Meda License, Development and Supply Agreements (Details) (USD $)	Dec. 31, 2012	Dec. 31, 2011
Summary of contractual rights, obligations and related cash flows
Total Milestones	$ 78,890,290	$ 73,890,290
Release of Milestones upon and subsequent to first sale	(77,416,811)	(59,735,570)
Remaining Deferred Revenue	1,473,479	14,154,720
North America [Member]
Summary of contractual rights, obligations and related cash flows
Total Milestones	61,341,570	61,341,570
North America [Member] | License rights to ONSOLIS (BEMA Fentanyl) [Member]
Summary of contractual rights, obligations and related cash flows
Total Milestones	59,800,000	59,800,000
North America [Member] | Non-cancer subsequent indication of product and further development of initial product [Member]
Summary of contractual rights, obligations and related cash flows
Total Milestones	1,541,570	1,541,570
Europe and Rest of World [Member]
Summary of contractual rights, obligations and related cash flows
Total Milestones	17,548,720	12,548,720
Europe and Rest of World [Member] | License rights to BREAKYL (BEMA Fentanyl) [Member]
Summary of contractual rights, obligations and related cash flows
Total Milestones	13,000,000	8,000,000
Europe and Rest of World [Member] | BREAKYL product through governmental approval in E.U. country [Member]
Summary of contractual rights, obligations and related cash flows
Total Milestones	$ 4,548,720	$ 4,548,720